AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy (AYU-STEP)
Effect of AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy: Prospective Pilot Study
Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 40% of patients treated with taxanes. These agents may cause burning pain, paresthesia, numbness, and loss of proprioceptive sensitivity, which can reduce well-being and impair quality of life.In this context, implementing non-pharmacological interventions, such as foot treatment/manipulation proposed in this project, represents a promising area to explore complementary therapies with minimal toxicity and low cost for symptom management.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Irene Feroce
- Phone Number: +39 0257489551
- Email: irene.feroce@ieo.it
Study Locations
-
-
-
Milan, Italy, 20141
- Recruiting
- European Institute of Oncology
-
Contact:
- Irene Feroce
- Phone Number: 0257489551
- Email: irene.feroce@ieo.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 anni
- Diagnosis of carcinoma with ongoing treatment or treatment completed within the previous 6 months with taxanes (paclitaxel/docetaxel).
- Grade 1-2 sensory-motor peripheral neuropathy (NCI-CTCAE v5).
- Able to walk independently.
- Written informed consent.
Exclusion Criteria:
- Pre-existing diabetic neuropathy
- Foot ulcers or infections
- Central neurological disorders
- Concomitant specific treatment for CINP including other complementary medicine. Occasional over the counter drugs such as NSIDs or pain killer are allowed. Any other clinical condition that, at the discretion of the physician or practitioner, may contraindicate participation in the study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment arm
Manual manipulation of the feet |
The treatment consists of manual manipulation of the feet using Mahanarayan oil. Each session lasts approximately 30-40 minutes and is performed with the patient in a supine position, including massage of the foot and lower leg. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients that completed the treatment
Time Frame: From enrollment to the follow-up contact at 10 weeks
|
Adherence to treatment will be measured as the number of subjects that completed all study treatment sessions on the total number of subjects enrolled. |
From enrollment to the follow-up contact at 10 weeks
|
|
Incidence of local adverse events related to the use of medicated oils during treatement sessions or manual therapy.
Time Frame: From enrollment to the follow-up contact at 10 weeks
|
Incidence will be calculated as the number of local adverse events related to the use of medicated oils during treatement sessions or manual therapy on the total number of treatment sessions administered. |
From enrollment to the follow-up contact at 10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale (QLQ-CIPN20) at 10 weeks.
Time Frame: From enrollment to the follow-up contact at 10 weeks
|
Impact of treatment on Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the QLQ-CIPN20 questionnaire. The QLQ-CIPN20 questionnaire will be administered four times: before the first treatment, at mid-treatment, at the end of treatment, and at follow-up. Higher the resulting score mean higher the CIPN affect the patient. Impact of treatment will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
|
Change from baseline in the score of The McGill Pain Questionnaire (P.R.I.) at 10 weeks.
Time Frame: From enrollment to the follow-up contact at 10 weeks
|
The McGill Pain Questionnaire (P.R.I.) will be administered before the first treatment, at the end of the treatment, and at follow-up. Higher the resulting score mean higher the paint felt by the patient. Impact of treatment on the reduction of the pain will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- UID 5323
- L2-657 (Other Identifier: Comitato Etico Lombardia 2)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.